The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Regeneron (REGN) and Sanofi (SNY) announce successful Phase 3 outcome for Dupixent in bullous pemphigoid, but not in chronic ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...